DGAP-News: Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific Officer, strengthening scientific focus
Retrieved on:
Monday, September 20, 2021
MSD, Biotechnology, Therapy, University of Cologne, CSO, Molecular biology, CDMO, Health, CMC, Rentschler, Institute, Senior, Biochemistry, Max Planck Institute of Biochemistry, Biology, CEO, CA, Acquisition, University, Science, Technology, Non-executive director, Drug development, CFO, VP, Scripps Research, Research, Institute for Genetic Engineering and Biotechnology Sarajevo, Quality of life, Supervisory board, Industry, Max Planck Society, Independent Board for Presbyterian Foreign Missions, Management, Fine chemical
Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific Officer, strengthening scientific focus
Key Points:
- Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific Officer, strengthening scientific focus
The issuer is solely responsible for the content of this announcement. - Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific Officer, strengthening scientific focus
Laupheim, Germany and Milford, MA, USA, September 20, 2021 - Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced the appointment of Dr. Christian Schetter, Ph.D. as Chief Scientific Officer (CSO) of Rentschler Biopharma SE, where he will be responsible for process technology and innovation, effective 15 September 2021. - Prof. Dr. Nikolaus F. Rentschler, Chairman of the Supervisory Board of Rentschler Biopharma, said: "I am delighted that Dr. Schetter has joined Rentschler Biopharma as our new Chief Scientific Officer.
- Dr. Christian Schetter, Rentschler Biopharma's new CSO, added: "Rentschler Biopharma is known to deliver very high quality based on solid science.